Introduction
============

Acute fibrinous and organizing pneumonia (AFOP) is a rare lung disease that was first reported in the year 2002 ([@b1-etm-0-0-3865]). The distinctive histopathological characteristics of AFOP are intra-alveolar fibrin deposits and associated organizing pneumonia, but without the classical hyaline membrane that is typically associated with diffuse alveolar disease. As only a small number of cases of AFOP have been reported to date, much ambiguity prevails over the clinical features, radiographic characteristics and prognoses of AFOP. In the present study, a patient diagnosed with AFOP, based on histopathological examination of a lung biopsy, is described. Based on a review of literature pertaining to documented AFOP cases, a summary of the clinical features, radiological characteristics, treatment outcomes and prognoses associated with AFOP is presented.

Case report
===========

A 39-year-old male presented with a 10-day history of high fever and cough with expectoration that was unresponsive to empirical treatment for pulmonary bacterial infection (moxifloxacin 0.4 g daily for 5 days; Bayer, Leverkusen, Germany) in January 2014 at Nanjing General Hospital of Nanjing Military Command (Nanjing, China). Serial chest computed tomography (CT) scans performed prior to hospitalization revealed enlarging bilateral lung lesions. There was no history of poisoning, exposure to dusty environmental conditions, smoking or alcohol intake. At the time of admission, the patient was looking ill, with slight dyspnea and pyrexia (39.2°C). Laboratory investigations revealed a white blood cell count of 4.6×10^9^ cells/l \[normal range (NR), 4--10×10^9^ cells/l\], differential neutrophil count of 68.6% (NR, 40--70%) and a C-reactive protein (CRP) level of 39.2 mg/l (NR, \<10 mg/l) in blood. The clotting parameters were normal. The blood biochemical indices were as follows: Alanine aminotransferase 124 U/l (NR, \<50 U/l), aspartate aminotransferase 124 U/l (NR, \<50 U/l), gamma-glutamyl transferase 72 U/l (NR, \<50 U/l), lactate dehydrogenase 779 U/l (NR, 90--250 U/l) and creatinine 36 µmol/l (NR, 40--110 µmol/l). The patient tested negative for human immunodeficiency virus. Arterial blood gas analysis revealed PaCO~2~ 28 mmHg, PaO~2~ 59 mmHg and pH 7.48 (FiO~2~, 40%). Sputum culture yield was negative. Tests for autoantibody and anti-Epstein-Barr virus, anti-mycoplasma and anti-influenza virus A antibody were negative. Chest CT showed bilateral lung consolidation, ground glass opacities and a small quantity of bilateral pleural effusion ([Fig. 1](#f1-etm-0-0-3865){ref-type="fig"}). A pulmonary biopsy specimen from the lower lobe confirmed the pathological diagnosis of AFOP ([Fig. 2](#f2-etm-0-0-3865){ref-type="fig"}); histopathological examination of lung biopsy specimen with hematoxylin and eosin stain (magnification, ×10) showed lymphocytic inflammatory infiltrate and fibroblast proliferation. After diagnosis, 500 mg methylprednisolone (Pfizer, Inc., New York, NY, USA) was administered for 3 days followed by 80 mg for 1 week, but the SpO~2~ of the patient could not be improved, and he succumbed to mortality 14 days after admission. The patient\'s wife provided written informed consent.

Literature review
=================

### General literature review

A literature search on PubMed ([www.ncbi.nlm.nih.gov/pubmed](www.ncbi.nlm.nih.gov/pubmed)) and Medline database ([www.embase.com](www.embase.com)) was performed between January 2015 and January 2016 using the key words 'acute fibrinous' and 'organizing pneumonia' or 'AFOP', and yielded a total of 42 articles. English language case reports were included, and manuscripts without adequate details were excluded. Furthermore, relevant Chinese language manuscripts were searched, and duplication was eliminated by combining the reports that happened to refer to the same patient. In addition, reports were removed that lacked data on clinical manifestations, imaging findings, treatment outcomes and prognosis. A total of 24 articles with reference information on 29 patients (including the patient in the present study) qualified for the literature review and served as the study population for the purpose of this analysis ([Table I](#tI-etm-0-0-3865){ref-type="table"}) ([@b2-etm-0-0-3865]--[@b25-etm-0-0-3865]). Of 29 patients, 20 were male and 9 were female; the median age was 55 years (range, 10--73 years). There was a considerable variability in the past medical history of AFOP cases and included hypertension, chronic nephrosis, hypothyroidism, diabetes mellitus, hematological disorders (leukemia and myelodysplastic syndrome), pulmonary diseases (cystic fibrosis, asthma and amiodarone-induced interstitial pneumonia), post-lung transplantation for cystic fibrosis, interstitial pneumonia and autoimmune diseases, such as systemic lupus erythematosus (SLE). Smoking appeared not to be a risk factor, since only 5 of the 29 patients had a history of smoking. In addition, 12 patients had no past medical history and were apparently healthy prior to the present illness.

### Clinical manifestation of AFOP

Clinical manifestation of AFOP appeared to lack specificity with patients presenting with pulmonary and/or extra-pulmonary symptoms. The most common pulmonary symptom was a cough (21/29 patients); 9 patients had a non-productive (dry) cough. Other less common symptoms included progressive dyspnea, cough with expectoration, chest pain and hemoptysis (2/29) ([Table II](#tII-etm-0-0-3865){ref-type="table"}). Vomiting was reported in 3 patients, indicating the probability of bacterial infection.

Fever was the other predominant manifestation, with 16 out of 29 patients having fever as their first symptom at the time of onset. The highest temperature recorded was 39.8°C, and rarely was it associated with chills and rigors. Most common extra-pulmonary symptoms included fatigue, anorexia, loss of weight and night sweats. However, these symptoms were not common.

The clinical presentation of AFOP in the present study included acute and sub-acute onset. The reported etiology was idiopathic, secondary to pulmonary infection, connective tissue disorders or adverse drug reactions. The onset of illness tended to vary with the etiology with apparently no predictable pattern being discernible. It was typically difficult to ascertain the exact time of onset. The time span from disease onset to initiation of medical treatment ranged between three days and eight months. A number of patients showed signs of infection, such as upper respiratory tract signs and symptoms, along with fever. The most important pulmonary sign was the presence of moist rales in both lower lobes of the lung (14/29 patients), but in 3 patients the abnormal pulmonary signs were confined to a unilateral lobe.

Laboratory tests demonstrated that a small number of patients (4/14) had elevated white blood cells, but the majority of patients (8/11) had elevated CRP. Immunologic tests and anti-neutrophil cytoplasmic antibodies were normal except in one patient with SLE. The various pathological investigations performed included transbronchial lung biopsy (TBLB) in one patient, thoracoscopic lung biopsy in three patients, open-lung biopsy in two patients and pulmonary puncture in 23 patients. All cases were diagnosed as AFOP on the basis of histopathological evidence.

### Chest imaging

A number of patients had multiple bilateral lung infiltrative shadows at onset; in these patients, the diagnosis was first suspected on the basis of chest radiography signs. Chest CT was more informative in delineating the pathological chest signs ([Table III](#tIII-etm-0-0-3865){ref-type="table"}).

### Treatment and prognosis

Hormone therapy was the mainstay of treatment in these patients, with initial dosage varying from prednisone 0.5 mg/kg/day to methylprednisolone 240 mg/day. The treatment regimen tended to vary among the patients. Likewise, there was a wide variability in treatment outcomes; ranging between complete resolution and partial resolution, and in case of four patients, deterioration leading to mortality.

Discussion
==========

AFOP is a rare pathological entity first described by Beasley *et al* ([@b1-etm-0-0-3865]). Following this, additional cases of AFOP have been reported. In 2013, the American Thoracic Society/European Respiratory Society statement defined AFOP as a subgroup of idiopathic interstitial lung disease with acute lung injury that is characterized by fibrin deposition in pulmonary alveoli and organization of loose connective tissue ([@b26-etm-0-0-3865]). The other characteristic feature is the absence of diffuse pulmonary alveolar injury, hyaline membrane formation and no eosinophil infiltration or granuloma formation ([@b26-etm-0-0-3865]). Although all cases were diagnosed on the basis of histopathological evidence, there were marked differences in clinical manifestations, treatment and prognosis.

AFOP is a group of illnesses marked by a considerable heterogeneity with respect to clinical and pathological changes. The disease etiology is idiopathic or secondary to other diseases, such as viral infection, connective tissue disorders and adverse drug reactions. Furthermore, owing to the heterogenous clinical presentation, the cause of AFOP is typically ambiguous.

The most common symptoms of AFOP identified in previous literature were cough, fever and dyspnea, while chest pain and hemoptysis were relatively less frequent. The clinical picture appears to be similar to that in other forms of idiopathic interstitial pneumonia; however, fever that is more common in AFOP as compared with other forms of interstitial pneumonia.

Radiographic chest findings included consolidation and bilateral ground-glass shadows with no low-density shadows. The clinical manifestations of AFOP have been summarized in a number of reports ([@b8-etm-0-0-3865],[@b10-etm-0-0-3865],[@b15-etm-0-0-3865],[@b17-etm-0-0-3865]). As per these reports, the majority of patients had presented with organizing pneumonia along with multiple plaques, and diffuse increase in dense shadows in pulmonary alveoli distributed in outer zone and bilateral boundaries ([@b15-etm-0-0-3865]). However, a small number of the patients presented with randomly distributed nodular shadows. The etiology as well as the pathological basis of AFOP requires further research in order to facilitate its distinction from tuberculosis and tumors.

Out of the four mortalities on record among the study population in the current report, there were 3 males and 1 female. The key distinguishing factors in this study was a higher proportion of cases with dyspnea and lack of nodular shadows on chest radiographs, while there was no significant difference in the proportion of patients manifesting fever. In addition, it was identified that the development of hydrothorax in AFOP was a poor prognostic indicator ([Table IV](#tIV-etm-0-0-3865){ref-type="table"}). However, findings from the present study require further evaluation and validation in larger series.

In conclusion, the current report presents a case of AFOP that has a rapid onset and progress, is not secondary to other diseases, shows no improvement in response to glucocorticoid hormone treatment and has a poor prognosis, and summarizes the key aspects of this rare disease based on a review of available published literature. Given the ambiguous etiology and heterogenous clinical presentation, there is likely to be a significant under-reporting of AFOP. In other words, the incidence rate of AFOP could be much higher than what has so far been reported in the literature. Therefore, the key clinical aspects underlined in this report should pave the way for further research on AFOP.

![Computed tomography of the chest showing bilateral lung consolidation, ground glass opacities (white arrow) and mild pleural effusion (black arrow).](etm-12-06-3958-g00){#f1-etm-0-0-3865}

![Histopathological examination of lung biopsy specimen with hematoxylin and eosin stain (left panel, magnification, ×10; right panel, magnification, ×40) showing lymphocytic inflammatory infiltrate and fibroblast proliferation.](etm-12-06-3958-g01){#f2-etm-0-0-3865}

###### 

Summary of literature reports on acute fibrinous and organizing pneumonia.

  Author                        No. reported patients   Ref.
  ----------------------------- ----------------------- ---------------------
  Guimarães *et al*, 2012       1                       [@b2-etm-0-0-3865]
  Kobayashi *et al*, 2005       1                       [@b3-etm-0-0-3865]
  Heo *et al*, 2010             1                       [@b4-etm-0-0-3865]
  Damas *et al*, 2006           1                       [@b5-etm-0-0-3865]
  Valim *et al*, 2012           1                       [@b6-etm-0-0-3865]
  Lee *et al*, 2009             1                       [@b7-etm-0-0-3865]
  Hariri *et al*, 2010          1                       [@b8-etm-0-0-3865]
  Otto *et al*, 2013            1                       [@b9-etm-0-0-3865]
  Feng *et al*, 2014            1                       [@b10-etm-0-0-3865]
  Labarinas *et al*, 2013       1                       [@b11-etm-0-0-3865]
  Rapaka *et al*, 2011          1                       [@b12-etm-0-0-3865]
  Bhatti *et al*, 2009          1                       [@b13-etm-0-0-3865]
  Renaud-Picard *et al*, 2015   1                       [@b14-etm-0-0-3865]
  Xu *et al*, 2014              1                       [@b15-etm-0-0-3865]
  Miao *et al*, 2010            1                       [@b16-etm-0-0-3865]
  Gui *et al*, 2012             2                       [@b17-etm-0-0-3865]
  Zhang *et al*, 2010           1                       [@b18-etm-0-0-3865]
  Qiu *et al*, 2013             5                       [@b19-etm-0-0-3865]
  Garcia *et al*, 2015          1                       [@b20-etm-0-0-3865]
  Piciucchi *et al*, 2015       1                       [@b21-etm-0-0-3865]
  Sauter and Butnor, 2014       1                       [@b22-etm-0-0-3865]
  Prahalad *et al*, 2005        1                       [@b23-etm-0-0-3865]
  Vasu *et al*, 2009            1                       [@b24-etm-0-0-3865]
  Yokogawa and Alcid, 2007      1                       [@b25-etm-0-0-3865]
  Present case, 2014            1                       

###### 

Main pulmonary and extrapulmonary symptoms of acute fibrinous and organizing pneumonia (AFOP).

  Symptoms         No. patients (n=29)
  ---------------- ---------------------
  Cough            21
  Expectoration    12
  Dyspnea          15
  Hemoptysis       2
  Chest pain       4
  Fever            16
  Fatigue          1
  Anorexia         2
  Loss of weight   1
  Night sweat      3

###### 

Primary imaging findings in acute fibrinous and organizing pneumonia.

  Imaging findings                             No. patients (n=28)^[a](#tfn1-etm-0-0-3865){ref-type="table-fn"}^
  -------------------------------------------- -------------------------------------------------------------------
  Ground-glass opacity                         13
  Consolidation                                24
  Nodular shadows                                8
  Strip/net shadow                               5
  Interlobular septal thickening                 1
  Unilateral lung                                2
  Distribution in both lower lobes               7
  Distribution near the pleura                   5
  Distribution in bronchial vascular bundles     7
  Low density shadow                             0
  Halo sign                                      3
  Reserved halo sign                             1
  Hydrothorax                                    6
  Pneumothorax                                   0

Computed tomography findings were not documented in one patient; 28 patients were enrolled.

###### 

Analysis of patients with poor prognosis.

  Grouping                        Mortality at post-treatment visit   Survival at post-treatment visit
  ------------------------------- ----------------------------------- ----------------------------------
  Age (±SD)                       39.3±19.0                           54.5±16.5
  Gender (male:female)            3:1                                 17:8
  Symptoms (n=29), n                                                  
    Dyspnea                       3/4                                 12/25
    Fever                         2/4                                 14/25
  Computed tomography (n=28), n                                       
    Ground-glass opacity          2/4                                 11/24
    Consolidation                 4/4                                 20/24
    Nodular shadows               1/4                                 7/24
    Hydrothorax                   3/4                                 3/24

SD, standard deviation.
